Cargando…

Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort

OBJECTIVE: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors. METHODS: This hospital-based retrospective cohort study included 447 women with breast cancer trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonçalves, Homero, Guerra, Maximiliano Ribeiro, Duarte Cintra, Jane Rocha, Fayer, Vívian Assis, Brum, Igor Vilela, Bustamante Teixeira, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Triple-Negative Breast Cancer - Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071162/ https://www.ncbi.nlm.nih.gov/pubmed/30083066 http://dx.doi.org/10.1177/1179554918790563

Ejemplares similares

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Outcomes of Immediate Breast Reconstruction in Triple Negative Breast Cancer
por: Grigor, Emma, et al.
Publicado: (2021)

Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics
por: Sheng, Dan-li, et al.
Publicado: (2022)

Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2015)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer
por: Yoen, Heera, et al.
Publicado: (2023)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women
por: de Freitas, Renata Mendes, et al.
Publicado: (2022)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

Two activating mutations of MPL in triple‐negative myeloproliferative neoplasms
por: Xie, Juan, et al.
Publicado: (2019)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

A component of lobular carcinoma in clinically lymph node–negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer
por: Van Wyhe, Renae D., et al.
Publicado: (2018)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis
por: Weichhaus, Michael, et al.
Publicado: (2014)

Comparison of Breast Reconstruction Outcomes Using Oxychlorosene versus Triple Antibiotic Solution for Pocket Irrigation
por: Bamba, Ravinder, et al.
Publicado: (2022)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

MicroRNAs in regulation of triple-negative breast cancer progression
por: Piasecka, Dominika, et al.
Publicado: (2018)

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer
por: Wang, Chao‐Qun, et al.
Publicado: (2016)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Lamin B2 promotes the progression of triple negative breast cancer via mediating cell proliferation and apoptosis
por: Zhao, Cui-Cui, et al.
Publicado: (2021)

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
por: Xu, Yonggang, et al.
Publicado: (2021)

Breast cancer survival and the health system in Brazil: an analysis of public and private healthcare
por: Ferreira, Adriana de Souza Sérgio, et al.
Publicado: (2023)

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
por: de Paula, Bruno, et al.
Publicado: (2023)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
por: Vinet, Mathilde, et al.
Publicado: (2019)

OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer
por: Ding, Xiaorong, et al.
Publicado: (2020)

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer
por: Fang, Wentong, et al.
Publicado: (2021)

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer
por: Li, Yaming, et al.
Publicado: (2019)

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study
por: Wu, Wenyu, et al.
Publicado: (2019)

Outcomes of Negative Pressure Wound Therapy on Immediate Breast Reconstruction after Mastectomy
por: Akhter, Haris M., et al.
Publicado: (2023)

CD25(high) Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
por: Fattori, Stéphane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f6hsd2pbo8vpe8nr8hj1rda68l